Bristol-Myers Squibb Company
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000DQLV23
BMY
Bristol-Myers Squibb Company
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Drug Manufacturers—General
NAME
Bristol-Myers Squibb Company
ISIN
US1101221083
TICKER
BMY
MIC
XNYS
REUTERS
BMY.N
BLOOMBERG
BMY US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Fr., 31.01.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC), based on result...
Bristol-Myers Squibb
Fr., 31.01.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory...
Bristol-Myers Squibb
Sa., 25.01.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Bristol Myers Squibb (NYSE: BMY) today announced results of an analysis from the ...
Bristol-Myers Squibb
Fr., 03.01.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Monday, January 13, 2025.
The company’s presentation and participation in a fireside chat will begin at 7:30 a.m. PT/10:30 a.m. ET.
The event will be webcast simultaneously at http://investor.bms.com, with materi...
Bristol-Myers Squibb
Fr., 27.12.2024
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human hyaluronidase (rHuPH20), in most previously approved adult, solid tumor Opd...
Bristol-Myers Squibb
Mo., 23.12.2024
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met their primary endpoint, with a significantly greater proportion of Sotyktu-t...
Bristol-Myers Squibb
Mo., 23.12.2024
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
“Colorectal cancer is th...
Bristol-Myers Squibb
Do., 19.12.2024
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2024 on Thursday, February 6, 2025. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date.
Investors and the general public are invited to listen to a li...
Bristol-Myers Squibb
Mi., 11.12.2024
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on February 3, 2025, to stockholders of record at the close of business on January 3, 2025.
This quarterly dividend represe...
Bristol-Myers Squibb
Mo., 09.12.2024
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) announced results from 18 presentations reinforcing its leadership in cell therapy, with data demonstrating efficacy, durability and safety of currently available therapies in blood cancers and highlighting the potential of its pipeline for future indications including autoimmune diseases. These results, covering a...
Bristol-Myers Squibb
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
